Buchumschlag

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Antonio Pinto, Marco Ladetto, Maurizio Martelli, Carlo Visco, Francesco Zaja, Emanuele Guardalben, Pier Luigi Zinzani
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
von: Mohammed Zuber, et al.
Veröffentlicht: (2024)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
von: Francesca Romana Mauro, et al.
Veröffentlicht: (2024)

Third‐Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance ( MGTS)
von: Louise Man, et al.
Veröffentlicht: (2025)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
von: Beatrice Casadei, et al.
Veröffentlicht: (2024)

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
von: Alessandro Broccoli, et al.
Veröffentlicht: (2025)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
von: Kenji Ishitsuka, et al.
Veröffentlicht: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
von: Monia Marchetti, et al.
Veröffentlicht: (2025)

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma
von: Sam Yuen, et al.
Veröffentlicht: (2024)

Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia
von: Tamer Othman, et al.
Veröffentlicht: (2024)

Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia
von: Nitin Chaudhary, et al.
Veröffentlicht: (2024)

A matching‐adjusted indirect comparison of survival outcomes with pirtobrutinib ( BRUIN ) versus standard of care ( SCHOLAR ‐2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor
von: Georg Heß, et al.
Veröffentlicht: (2025)

Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study
von: Aung M. Tun, et al.
Veröffentlicht: (2024)

Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy
von: Hu Qian, et al.
Veröffentlicht: (2024)

How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
von: Nayla Mouawad, et al.
Veröffentlicht: (2024)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
von: Pier Luigi Zinzani, et al.
Veröffentlicht: (2025)

Management of post‐autologous transplant relapse in patients with T‐cell lymphomas
von: Olivier Veilleux, et al.
Veröffentlicht: (2024)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
von: Jiangfang Feng, et al.
Veröffentlicht: (2024)

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy
von: Matthew A. Lunning, et al.
Veröffentlicht: (2024)

350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES
von: A. Guidetti, et al.
Veröffentlicht: (2025)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
von: Elisabetta M. Abenavoli, et al.
Veröffentlicht: (2024)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
von: Francesca Maria Quaglia, et al.
Veröffentlicht: (2026)

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia
von: Qiu‐Sha Huang, et al.
Veröffentlicht: (2025)

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
von: José Carlos Jaime‐Pérez, et al.
Veröffentlicht: (2024)

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report
von: Anna Nikkarinen, et al.
Veröffentlicht: (2024)

Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
von: Tze Wei Chan, et al.
Veröffentlicht: (2025)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Veröffentlicht: (2025)

Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML
von: Stefan O. Ciurea, et al.
Veröffentlicht: (2024)

Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients
von: Sanfang Tu, et al.
Veröffentlicht: (2024)

Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy
von: Nicholas J. Short, et al.
Veröffentlicht: (2024)

Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53‐mutant mantle cell lymphoma
von: Manik Uppal, et al.
Veröffentlicht: (2025)

Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk
von: Thomas Erblich, et al.
Veröffentlicht: (2024)

855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE
von: K. Cwynarski, et al.
Veröffentlicht: (2025)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
von: Kaitlin Annunzio, et al.
Veröffentlicht: (2024)

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease
von: A. Bernardelli, et al.
Veröffentlicht: (2026)

Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real‐world cohort analysis
von: Adam S. Kittai, et al.
Veröffentlicht: (2024)

133 | LONG‐TERM SURVIVAL TRENDS IN ADVANCED‐STAGE MANTLE CELL LYMPHOMA: A POOLED ANALYSIS OF SIX RANDOMIZED PHASE III TRIALS FROM 1996 TO 2020
von: L. Jiang, et al.
Veröffentlicht: (2025)

Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study
von: Nilanjan Ghosh, et al.
Veröffentlicht: (2024)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
von: Idanna Innocenti, et al.
Veröffentlicht: (2024)

Erratum to: Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial
Veröffentlicht: (2024)

847 | PALT TRIAL: FIRST IN CLASS GLYCO‐HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA
von: G. Damaj, et al.
Veröffentlicht: (2025)